Immutep Ltd has released a press release.
Disclosure Under LR 3.10.5A and 7.1A.4(b)
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Form 6-K
- USD 5 Million Capital Raising
- IMP321 demonstrates positive safety & efficacy qualities
- Approval received to commence 3rd cohort of melanoma trial
- $492k R&D Tax Incentive Refund Received
Later from Immutep
- Approvals received to initiate INSIGHT clinical trial
- 2nd milestone payment to be received from Novartis
- Financial Update
- French government research cash rebate of A$1.3M received
- Appendix 4E & 2017 Full Year Statutory Accounts
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep